Basic information Safety Supplier Related

CTOP

Basic information Safety Supplier Related

CTOP Basic information

Product Name:
CTOP
Synonyms:
  • threoninamide
  • NALTRIBEN
  • NTB
  • D-PHE-CYS-TYR-D-TRP-ORN-THR-PEN-THR AMIDE
  • D-PHE-CYS-TYR-D-TRP-ORN-THR-PEN-THR-NH2
  • DPHE-CYS-TYR-DTRP-ORN-THR-PEN-THR-OL
  • CTOP
  • CYS2,TYR3,ORN5,PEN7-AMIDE
CAS:
103429-31-8
MF:
C50H67N11O11S2
MW:
1062.26
Product Categories:
  • peptide
  • Neuropeptides
  • Opioid Peptides
  • Other Opioid Peptides
  • Other Opioid PeptidesPeptides for Cell Biology
  • Opioid receptor and opioid-like receptor
Mol File:
103429-31-8.mol
More
Less

CTOP Chemical Properties

Boiling point:
1491.2±65.0 °C(Predicted)
Density 
1.42±0.1 g/cm3(Predicted)
RTECS 
XO8578200
storage temp. 
-20°C
pka
9.90±0.15(Predicted)
form 
Powder
color 
white
Water Solubility 
Soluble to 1 mg/ml in water
Sequence
{D-Phe}-Cys-Tyr-{D-Trp}-{Orn}-Thr-{Pen}-Thr-NH2 (Disulfide bridge:Cys2-Pen7)
More
Less

Safety Information

WGK Germany 
3

MSDS

More
Less

CTOP Usage And Synthesis

Uses

CTOP is a μ-opioid receptor antagonist which has been shown to regulate behaviour and expression in rats. An endogenous opioid peptide which may also be used in the treatment of pain through improved morphine tolerance via blocking of mTOR.

Uses

CTOP has been used:

  • to study the anxiogenic effects induced by CTOP in mice and rat.
  • to study the effect of μ-opioid antagonist, CTOP on the bovine milk-derived LF (BLF)-induced analgesia.
  • to determine whether μ-opioid receptors act cooperatively with 5-hydroxytryptamine (5-HT1A) receptors to regulate the behaviors generated in the elevated T-maze (ETM).

General Description

D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) is a selective cyclic μ-opioid receptor antagonist.

Biochem/physiol Actions

Selective ligand for μ-opioid receptors.

in vivo

CTOP (0-0.5 nmol, ICV, once) antagonizes the analgesic effect of morphine in a dose-dependent manner[1].
CTOP (0-2 nmol, ICV, once) causes withdrawal hypothermia and a loss of body weight in morphine-dependent animals[1].
CTOP (0-1.5 nmol per side, Intra-VTA injection) enhances extracellular dopamine levels in the nucleus accumbens and dose-dependently enhances locomotor activity[2].

Animal Model:Male CFLP mice (25-30 g)[1]
Dosage:0, 0.001, 0.05, 0.075, 0.1, and 0.5 nmol (made up in artificial cerebrospinal fluid (CSF) and kept in plastic tubes at -25℃ until use)
Administration:Intracerebroventricular (i.c.v.) administration, once
Result:Antagonized the analgesic effect of morphine in a dose-dependent manner, antagonized the morphine-induced hypermotility in a dose-dependent manner.
Animal Model:Male CFLP mice (25-30 g, Acute dependence to morphine was induced by a single dependence-inducing (100 mg/kg) dose of morphine-HC1)[1]
Dosage:0, 0.001, 0.05, 0.2, and 2 nmol
Administration:Intracerebroventricular (i.c.v.) administration, once
Result:Decreased the body temperature in a dose-dependent manner, and caused withdrawal hypothermia and a loss of body weight in morphine-dependent animals.
Animal Model:Long-Evans hooded rats (12, male, 350-450 g)[2]
Dosage:0, 0.015, 0.15, and 1.5 nmol per side
Administration:Intra-VTA (ventral tegmental area) injection
Result:Enhanced extracellular dopamine levels in the nucleus accumbens, dose-dependently increased activity, whereas had no effect on feeding and drinking behavior.

IC 50

μ Opioid Receptor/MOR

storage

Store at -20°C

CTOPSupplier

3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
GL Biochem (Shanghai) Ltd
Tel
21-61263452 13641803416
Email
ymbetter@glbiochem.com
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Cellmano Biotech Limited
Tel
0551-65326643 18156095617
Email
info@cellmano.com